35 results about "Diabetic neuropathy" patented technology

The invention provides a diabetic neuropathy dynamic early warning method based on a multi-modal biological signal, and the method comprises the steps: integrating a multi-modal sensor through an intelligent wearable device, and constructing a personalized prediction model in combination with a deep learning algorithm; through an artificial intelligence algorithm, diabetic neuropathy (DN) development risk prediction and unperceptual hypoglycemia real-time early warning are realized. According to the time-frequency domain characteristics and clinical data of the multi-mode signal, the time window of the DN from the progress to the serious stage can be predicted; recognizing an unperceptual hypoglycemia risk by combining ECG and HR features with a blood glucose trend prediction model, and triggering grading intervention measures; based on the individual physiological response mode of the patient, the algorithm threshold is dynamically optimized, and the accuracy of prediction and early warning is improved. According to the method, HR, BP, ECG and other multi-dimensional signals are integrated, and the prediction precision is improved; continuous monitoring and instant feedback are supported; the self-adaptive algorithm adapts to individual differences of patients, and the limitation of a traditional general model is overcome.

The invention relates to the technical field of medical information, and discloses a diabetic neuropathy dynamic early warning method based on deep learning. The method comprises the following steps: acquiring multi-modal physiological data through a sensor array, and converting the multi-modal physiological data into a feature vector sequence through preprocessing and pathophysiology-based mapping; the core of the method is that a dynamic feature selection mechanism is adopted to adaptively screen out a feature subset most related to neuropathy progress to replace a traditional fixed feature set; and constructing a multi-time scale risk prediction model, generating an individualized risk evolution track, and setting a dynamic early warning threshold according to the individualized risk evolution track. And triggering graded early warning by comparing the real-time risk index with a personalized threshold value, and completing adaptive updating of the model. The accuracy of individual risk signal capturing is improved through dynamic feature selection, real prospective early warning is achieved based on a dynamic threshold value of an individual trajectory, and therefore the accuracy and timeliness of early warning are improved.

The present invention relates to novel compounds and pharmaceutical compositions thereof, and to methods for promoting healthy skin aging, treating skin disorders, treating cardiovascular disorders, treating renal disorders, treating angiogenesis disorders, such as cancer, treating tissue damage, such as non-cardiac tissue damage, treating progressive myocardial infarction, and treating various other disorders, such as complications resulting from diabetes with the compounds and compositions of the invention. Other disorders may include, but are not limited to, atherosclerosis, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, skin infections, peripheral vascular disease, stroke, and the like.

To enhance inspection efficiency of diabetic neuropathy.SOLUTION: A first inspection device 21 acquires a stimulation perception threshold of a subject S being at a predetermined place by stimulating the peripheral nerves of the subject S. A second inspection device 22 stimulates dorsoventral nerves and tibial nerves of the subject S by flowing current to a stimulation electrode 212 worn on the subject S and thereby acquires induction electromyogram from the subject S being at the predetermined place. An evaluation device 23 evaluates the seriousness of a diabetic neuropathy based on a seriousness reference proposed by Dr. Baba of the subject S on the basis of the stimulation perception threshold and the induction electromyogram. An output device 24 outputs a result of the evaluation by the evaluation device 23.SELECTED DRAWING: Figure 3

The invention discloses a tricyclic compound and an application of the tricyclic compound in a medicine, and particularly relates to a novel tricyclic compound and a medicine composition containing the novel tricyclic compound. The invention further relates to a preparation method of the compound and application of the compound or the pharmaceutical composition in preparation of drugs for treating GPR84 antagonist mediated diseases and / or symptoms, in particular to application of the compound or the pharmaceutical composition in preparation of drugs for treating non-alcoholic fatty liver diseases, inflammatory bowel diseases, idiopathic pulmonary fibrosis and diabetic neuralgia.

A system for the manufacture of pharmaceutical formulations for the treatment of diabetes and diabetic neuropathy, comprising: a) an extraction unit for producing an ethanolic extract from shade-dried leaves of Moringa oleifera Lam. and Bacopa monnieri Linn., and defatting the dried, crushed leaves with petroleum ether to remove lipids and chlorophyll; b) a fractionation unit configured to fractionate the ethanolic extract with ethyl acetate to obtain the ethyl acetate fraction; c) a phytosome preparation unit for the production of phytosomes using antisolvens precipitation technology, wherein the phytosome preparation unit comprises the following: • an ultrasonic device for sonicating a mixture of ethyl acetate fraction and phosphatidylcholine, • a heating device configured to heat the sonicated mixture below 40 °C, and • a condensation device configured to condense solvents into a complex film; and d) a formulation unit configured to incorporate the phytosomes into pharmaceutical dosage forms.

The present invention provides a compound having a PDHK inhibitory activity and useful for the treatment or prophylaxis of diabetes (type 1 diabetes, type 2 diabetes etc.), insulin resistance syndrome, metabolic syndrome, hyperglycemia, hyperlactacidemia, diabetic complications (diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, cataract etc.), cardiac failure (acute cardiac failure, chronic cardiac failure), cardiomyopathy, myocardial ischemia, myocardial infarction, angina pectoris, dyslipidemia, atherosclerosis, peripheral arterial disease, intermittent claudication, chronic obstructive pulmonary disease, brain ischemia, cerebral apoplexy, mitochondrial disease, mitochondrial encephalomyopathy, cancer, pulmonary hypertension or Alzheimer disease. The present invention relates to a compound of the formula [I-a] or the formula [II], or a pharmaceutically acceptable salt thereof:wherein each symbol means the same as that described in the specification.

DRUG DELIVERY SYSTEM USING PHYTOCONSTITUENTS FOR TREATMENT OF DIABETIC NEUROPATHY

The application discloses application of a glucose transporter 1 inhibitor in preparation of a drug for treating diabetic neuropathy. The application verifies that the glucose transporter 1 inhibitor BAY-876 can be used as a drug for treating diabetic peripheral neuropathy and can be combined with mecobalamin to be used as a drug for treating diabetic peripheral neuropathy through pharmacodynamics experiments.

The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for promoting healthy aging of skin, the treatment of skin disorders, the treatment of cardiovascular disorders, the treatment of renal disorders, the treatment of angiogenesis disorders, such as cancer, treatment of tissue damage, such as non-cardiac tissue damage, the treatment of evolving myocardial infarction, the treatment of ischemic injury, and the treatment of various other disorders, such as complications arising from diabetes with the compounds and compositions of the invention. Other disorders can include, but are not limited to, atherosclerosis, cardiomyopathy, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, diabetic cardiomyopathy, infections of the skin, peripheral vascular disease, stroke, galactosemia, asthma, PMM2-CDG and the like.

The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for promoting healthy aging of skin, the treatment of skin disorders, the treatment of cardiovascular disorders, the treatment of renal disorders, the treatment of angiogenesis disorders, such as cancer, treatment of tissue damage, such as non-cardiac tissue damage, the treatment of evolving myocardial infarction, the treatment of ischemic injury, and the treatment of various other disorders, such as complications arising from diabetes with the compounds and compositions of the invention. Other disorders can include, but are not limited to, atherosclerosis, cardiomyopathy, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, diabetic cardiomyopathy, infections of the skin, peripheral vascular disease, stroke, galactosemia, asthma, PMM2-CDG and the like.

This application relates to the field of traditional Chinese medicine pharmaceutical technology, and discloses a traditional Chinese medicine for treating diabetic neuropathy and its preparation method. The traditional Chinese medicine is prepared from Coptis chinensis, Corydalis yanhusuo, Schisandra chinensis, Cornus officinalis, Astragalus membranaceus, and Cinnamomum cassia. The preparation method includes: low-temperature differential pretreatment of the raw materials; gas-phase assisted mechanical activation of components A and C under pressurized carbon dioxide environment, utilizing in-situ generation of carbamate intermediates in the gas phase to reduce lattice energy; subsequently, component B is added and pulsed milling is performed, directionally assembling into a hydrophobic ion-pair complex through a thermodynamically driven ligand substitution reaction; finally, the pressure and temperature are increased in situ to convert the reaction medium into a supercritical fluid for integrated extraction. This invention achieves the transformation of the active ingredient from a hydrophilic to a lipophilic chemical form through a gas-phase activation and stepwise substitution strategy, enabling it to effectively penetrate the blood-nerve barrier. Simultaneously, the low-temperature, anaerobic environment throughout the process effectively avoids the degradation of heat-sensitive components.

The present invention relates to the use of botulinum toxins for the treatment of peripheral neuropathic pain (PNP) by topical administration of botulinum toxins. The administration includes subcutaneously injecting an effective amount of botulinum toxin into a region of the skin of the patient affected by pain according to a specific administration regimen. The peripheral neuropathic pain may be, for example, post-herpes zoster neuralgia, peripheral nerve injury (e.g., due to surgery or trauma), trigeminal neuralgia, painful polyneuropathy (e.g., diabetic neuropathic pain), and painful nerve root disease.

The invention provides a nutritional composition. The nutritional composition consists of vitamin D, vitamin B2, vitamin B6, vitamin B12, folic acid and acceptable auxiliary materials. The composition can be used for preparing products for preventing or improving diabetic neuropathy. In addition, the compound preparation form of the composition is beneficial to improving the taking compliance and saving the total cost.

The invention discloses a tricyclic compound and an application of the tricyclic compound in a medicine, and particularly relates to a novel tricyclic compound and a medicine composition containing the novel tricyclic compound. The invention further relates to a preparation method of the compound and application of the compound or the pharmaceutical composition in preparation of drugs for treating GPR84 antagonist mediated diseases and / or symptoms, in particular to application of the compound or the pharmaceutical composition in preparation of drugs for treating non-alcoholic fatty liver diseases, inflammatory bowel diseases, idiopathic pulmonary fibrosis and diabetic neuralgia.

The application provides a kind of diabetic neuropathy dynamic early warning method based on multi-modal biological signal, through the integration of multi-modal sensor of intelligent wearable device, combine deep learning algorithm to construct individualized prediction model, realize the risk prediction of diabetic neuropathy (DN) progression and real-time warning of unconscious hypoglycemia through artificial intelligence algorithm.Can according to the time-frequency domain characteristics of multi-modal signal and clinical data, predict the time window of DN progression to serious stage;Through ECG and HR characteristics combined with blood glucose trend prediction model, identify the risk of unconscious hypoglycemia, and trigger graded intervention measures;Based on the physiological response mode of individual patient, dynamically optimize the threshold of algorithm, improve the accuracy of prediction and early warning.The application integrates HR, BP and ECG and other multi-dimensional signals, improves the prediction accuracy;Support continuous monitoring and instant feedback;Through adaptive algorithm to adapt to individual differences of patients, overcome the limitations of traditional general model.

This disclosure relates to compounds of formula (I-1) or (I-2): This relates to TIFF2026513962000575.tif74102. The compounds of this disclosure can inhibit the activity of tyrosine kinase 2 (TYK2), for example, in inflammation, autoimmune diseases, neuroinflammation, arthritis, rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, lupus nephritis, arthritis, osteoarthritis, gouty arthritis, pain, fever, pulmonary sarcoidosis, silicosis, cardiovascular disease, atherosclerosis, myocardial infarction, thrombosis, congestive heart failure and cardiac reperfusion injury, cardiomyopathy, stroke, ischemia, reperfusion injury, cerebral edema, head trauma, neurodegeneration, liver disease, inflammatory bowel disease, Crohn's disease, ulcerative colitis, nephritis, retina It is useful in treating diseases or disorders such as inflammation, retinopathy, macular degeneration, glaucoma, diabetes (type 1 and type 2), diabetic neuropathy, viral and bacterial infections, myalgia, endotoxin shock, toxic shock syndrome, autoimmune diseases, osteoporosis, multiple sclerosis, endometriosis, menstrual pain, vaginitis, candidiasis, cancer, fibrosis, obesity, muscular dystrophy, polymyositis, dermatomyositis, autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, vitiligo, alopecia, Alzheimer's disease, skin flushing, eczema, psoriasis, atopic dermatitis, and sunburn. This disclosure further provides a method for preparing the compound.

A MG53 variant, a fusion protein comprising a MG53 variant (e.g., a fusion protein comprising a MG53 variant and Fc) and uses thereof in treating or preventing diseases selected from heart diseases, diabetic cerebrovascular diseases, diabetic ocular complications, diabetic neuropathy, diabetic foot, kidney diseases, and diseases associated with cellular and / or tissue damage.

The invention provides compositions and methods to treat diabetic neuropathies. In particular, the invention provides combinations of at least two types of antioxidants have complementary effects for use against diabetic neuropathies. The two types of antioxidants include: antioxidants that comprise stabilizing heteroatoms and antioxidants with extended conjugated segments in a ring structure. At least one of each type of provided antioxidant has a pro-oxidative or conditionally pro-oxidative effect.

This invention relates to the field of pharmaceutical technology, disclosing the application of a synthetic peptide that targets and inhibits GRP in the preparation of a drug for treating diabetic neuropathy. The synthetic peptide sequence is SWYLILRIENGKLVKEVVHVPD. This sequence targets and blocks the GRP / vimentin signaling axis. Vimentin is specifically expressed by astrocytes and is a characteristic protein of astrocyte activation. Astrocyte activation can cause central sensitization, leading to chronic pain and other chronic diseases. This synthetic peptide sequence is used in the preparation of a drug for treating diabetic neuropathy. This invention provides a GRP-targeting inhibitory peptide that has a good therapeutic effect on chronic pain, laying the foundation for clinical treatment of chronic pain and possessing significant application and promotion value.

The invention discloses a drug for targeted therapy of diabetic peripheral neuropathy and a neuroprotection drug for regulating and controlling the proliferation function of Schwann cells, and relates to the technical field of biological medicines.The drug for targeted therapy of diabetic peripheral neuropathy comprises functional polypeptide CAP229, the amino acid sequence of the functional polypeptide CAP229 is shown as SEQ ID NO: 1, and the functional polypeptide CAP229 is a functional polypeptide CAP229. The functional polypeptide CAP229 is applied to a protein drug for targeted therapy of diabetic peripheral nerve demyelination, a new selection for targeted therapy of diabetic peripheral neuropathy is provided, and the CAP229 polypeptide has the advantages of small molecule, stable structure, endogenous source and the like, is suitable for a protein drug platform and a gene delivery strategy, has a good transformation prospect, and can be widely applied to the field of targeted therapy of diabetic peripheral nerve demyelination. The myelin sheath loss in diabetic neuropathy can be relieved in vitro and in animal models, and the method can be used for constructing a function screening platform and a high-throughput evaluation model.

The application discloses a drug for targeted treatment of diabetic peripheral neuropathy and a nerve protection drug for regulating Schwann cell proliferation function, relates to the technical field of biological medicine, and the drug for targeted treatment of diabetic peripheral neuropathy comprises a functional polypeptide CAP229, and the amino acid sequence of the functional polypeptide CAP229 is shown as SEQ ID NO:1. The functional polypeptide CAP229 is applied to a protein drug for targeted treatment of diabetic peripheral nerve demyelination, a new selection of targeted treatment of diabetic peripheral neuropathy is provided, the CAP229 polypeptide has the advantages of small molecule, stable structure, endogenous source and the like, is suitable for a protein drug platform and a gene delivery strategy, has good conversion prospect, can relieve myelin loss in diabetic neuropathy in vitro and in an animal model, and can be used for constructing a functional screening platform and a high-throughput evaluation model.

The invention provides a multi-mode ultrasonic evaluation method and system for treating diabetic neuropathy through traditional Chinese medicine. The method comprises the steps that firstly, multi-mode ultrasonic data containing the nerve cross sectional area, the Young modulus value and intra-nerve blood perfusion information are obtained from a target nerve; the method comprises the following steps: applying non-toxic spray gel containing specific modified core-shell structure quantum dots to the surface of a tongue coat to mark tongue coat epithelial cells or microbiota, then applying a standardized low-energy pulse type ultrasonic perturbation field, meanwhile, exciting the quantum dots by using low-power laser, and monitoring in real time by using a time-dependent single photon counting technology to obtain relaxation data; generating syndrome dynamic response fingerprints based on the data, and mapping the fingerprints to traditional Chinese medicine syndromes such as qi deficiency and blood stasis through a machine learning model; and finally, according to the multi-mode ultrasonic data and the syndrome dynamic response fingerprint, dynamically monitoring the change of the nerve-related indexes and the syndrome dynamic response fingerprint before and after treatment. According to the method, traditional Chinese medicine syndrome differentiation type objective quantitative evaluation is realized, subjective defects are overcome, and the curative effect is accurately monitored.

The current invention discloses methods for treating diseases characterized by elevated levels of the urokinase plasminogen activator receptor (uPAR) protein D2D3 wherein the disease is one or more of chronic kidney disease, insulin-dependent diabetes, or diabetic neuropathy. In addition, the invention provides methods for restoring pancreatic β-cell number and function in the pancreas of a subject diagnosed with insulin-dependent diabetes wherein the insulin-dependent diabetes is characterized by the presence of detectable levels of D2D3 Specifically, the methods comprise administration of a therapeutically effective amount of an agent that antagonizes or removes D2D3 from the circulation of the subject wherein the agent comprises an anti-D2D3 antibody or antigen binding fragment thereof that specifically binds to a D2D3 protein. Alternatively, the methods comprise removing the D2D3 protein from the circulation of the subject by an extracorporeal procedure.

The invention belongs to the technical field of medical detection, and discloses application of the concentration of HPD in plasma as a biomarker for identifying painful and painless diabetic neuropathy. According to the invention, the plasma HPD concentration is determined as an objective biomarker for distinguishing PDN and NPDN for the first time, and the limitation that the prior art depends on subjective symptom evaluation is overcome. By detecting the plasma HPD concentration which is an objective index, a reliable laboratory basis can be provided for pain subtype typing of diabetic neuropathy, so that a more accurate and effective individualized treatment scheme is guided to be clinically formulated, and the prognosis of a patient is finally improved. The detection method shows excellent identification capability, the AUC of a prediction model containing HPD can reach 0.88 and is obviously superior to a traditional index, and the detection method is mature and stable, samples are convenient to obtain, and the detection method is suitable for being widely applied to clinical examination.

This invention relates to the field of medical image processing and disease-aided diagnosis technology, specifically to an auxiliary detection system for diabetic neuropathy based on ophthalmic images. The system comprises a fundus image acquisition module, a hysteresis analysis module, a region fusion module, a microaneurysm influence degree acquisition module, and a diabetic neuropathy detection module. It analyzes the grayscale change characteristics of pixels in FFA images to obtain the hysteresis degree of pixel filling with fluorescein. Then, it performs region fusion based on the hysteresis degree, and quantifies the influence degree of microaneurysms based on the average hysteresis degree and area of ​​the fused region, thereby enabling the diagnosis of diabetic neuropathy. This invention quantifies the filling and diffusion patterns of fluorescein in and around microaneurysms to obtain the influence degree of microaneurysms, thus enabling auxiliary detection of diabetic neuropathy. This assists doctors in efficiently and accurately detecting diabetic neuropathy, effectively improving diagnostic efficiency and accuracy.

The invention relates to a composition that can reduce the effects of type 2 diabetes mellitus by lowering the HbA1c value. The invention provides a composition comprising a balanced mix of vitamins, minerals, co-factors, and fruit and plant extracts, with soursop fruit extract making a particularly important contribution. Furthermore, the composition can also reduce the effects of diabetic neuropathy.

The invention relates to CXCL8 inhibitors for use in the treatment of diabetes-associated comorbidities selected from non-proliferative diabetic retinopathy and / or diabetic neuropathy.

This invention provides a method, device, equipment, and storage medium for assessing the risk of diabetic neuropathy, relating to the field of medical data processing technology. The method includes: acquiring physiological data and treatment behavior data of a target user related to neuropathy; calculating treatment adherence indicators for the target user based on the treatment behavior data; inputting the treatment adherence indicators and key physiological data of neuropathy into a trained neuropathy early warning model to obtain the neuropathy risk probability of the target user; wherein, the neuropathy early warning model is constructed based on the relationship between neuropathy characteristics in the fundus and foot and the severity of neuropathy. This invention can help identify high-risk individuals early, adjust intervention plans in a timely manner, reduce the probability of serious complications, and balance the scientific rigor and practicality of the assessment.